Benefits
Sustained 5-hour alertness
A single 300 mg dose raised alertness scores above placebo at 1, 3 and 5 hours post-dose in one crossover trial of 59 adults. The published report gives a p value only for the 3-hour point (p = 0.042), and the change is small, around 12 milliseconds on the alertness score, so the 5-hour figure is suggestive rather than established. No trial has compared it with other caffeine-free alertness ingredients.
Acute attention and reaction time
A single 300 mg dose improves alertness, simple reaction time, and correct responses while reducing errors. Those results come from a separate manufacturer-funded crossover study in 62 adults, published in a journal PubMed does not index, so they cannot be checked in the usual databases. That study reported significantly more correct responses on the Symbol Digit Coding test at 30 minutes and 2 hours, higher Alertness Rating Scale scores at 2 and 5 hours, and faster simple reaction time at 2 and 5 hours. The multiples quoted are ratios of change from baseline rather than of the scores themselves, which makes the gap sound larger than it is. In the PubMed-indexed trial, reaction time gains reached significance only when the extract was taken with caffeine.
Caffeine-free profile
Produces no jitters, anxiety, or sleep disruption — unlike caffeine-based energy supplements. Evening use has some support: the 12-week trial dosed twice a day, after breakfast and in the evening, and sleep quality on the Pittsburgh Sleep Quality Index stayed unchanged in every arm. It has not been studied in children or in pregnancy and should not be offered as an option for either, and no trial has enrolled people with anxiety disorders or heart conditions, so it should not be recommended to them as a caffeine substitute. Useful for consumers moving away from caffeine.
Reduced fatigue and daytime sleepiness
Lower fatigue scores at 6 to 7 hours and lower Epworth Sleepiness Scale scores at 1, 2 and 5 hours were reported in manufacturer-funded studies published in journals PubMed does not index. The one PubMed-indexed trial that measured the Epworth scale, over 12 weeks, found daytime sleepiness fell in the extract group but the change was not statistically significant. No trial has been run in shift workers or across a night shift, so fatigue and sleepiness are the weakest part of this ingredient's evidence.
DNA-authenticated species identity
Alpinia galanga is frequently adulterated with closely related species (A. officinarum, A. zerumbet, A. calcarata) in the botanical supply chain. OmniActive states that it DNA-authenticates the species. The substitution problem is genuine and documented in the botanical literature, mostly involving A. officinarum and A. calcarata being sold in place of A. galanga, so this is a real supply-chain point. It is the supplier's own quality claim, though, and not something any trial tested.
Synergy with caffeine
In the single-dose trial, the combination with caffeine cut mean response time by 15.55 milliseconds at 3 hours (p = 0.026), which the authors read as blunting the caffeine dip at that point. The trial did not show a higher alertness peak or a longer effect for the combination than for either ingredient on its own, so that stronger claim is not supported. Pairing it with a smaller caffeine dose is a reasonable idea, but it rests on this single 3-hour result.
Mechanism of action
Dopamine modulation
Preclinical molecular studies indicate Alpinia galanga's diarylheptanoids modulate dopamine concentrations and dopamine receptor activity — the neurotransmitter system most directly linked to alertness, focus, and motivation. Mechanism distinct from caffeine's adenosine antagonism.
Acetylcholinesterase (AchE) inhibition
Laboratory and animal work shows A. galanga components inhibiting AchE, the enzyme that breaks down acetylcholine. This has not been measured in any of the human trials. Increased synaptic acetylcholine supports attention, learning, and memory. Same enzyme class targeted by Alzheimer's medications (donepezil, galantamine, rivastigmine) — though enXtra's effect is milder and not clinically positioned for cognitive decline.
No adenosine receptor activity
Unlike caffeine (which blocks adenosine receptors causing alertness plus vasoconstriction and habituation), enXtra works through different pathways. This is offered as the reason enXtra produces alertness without the typical caffeine side effects. Rebound fatigue and tolerance were not measured directly in any trial. On late-day use there is some evidence: the 12-week trial dosed twice a day, after breakfast and in the evening, and sleep quality on the Pittsburgh index stayed unchanged in all three arms, though sleep was measured by questionnaire rather than in a sleep laboratory.
No habit-forming tendency
A 12-week trial and a 4-week crossover study both found the benefit still present at the end of supplementation, which argues against tolerance developing. Withdrawal and dependence were not among the outcomes any of these trials reported, so the absence of dependence has not actually been tested. Distinguishes enXtra from caffeine, which develops tolerance within weeks and requires escalating doses for equivalent effect.
Clinical trials
Randomized, placebo-controlled trial evaluating 300 mg enXtra alone, 300 mg enXtra + caffeine, and caffeine alone vs placebo for acute alertness effects. Alertness scores measured at 1, 3, and 5 hours post-dose. Published in the Journal of the American College of Nutrition by Srivastava et al. 2017.
59 healthy adults aged 18 to 40 with moderate habitual caffeine intake. Acute single-dose crossover trial with four arms: placebo, extract, caffeine, and the combination.
Alertness scores rose from baseline by about 12 milliseconds at 1, 3 and 5 hours in the extract arm, with a p value reported only for the 3-hour point (p = 0.042). In the extract plus caffeine arm, mean response time fell by 15.55 milliseconds at 3 hours (p = 0.026), which the authors described as impeding the caffeine crash and improving sustained attention. The paper does not report the combination beating either ingredient alone on peak alertness. Sleep architecture, safety and tolerability were also assessed. Funded by the ingredient manufacturer.
Randomized, double-blind, placebo-controlled crossover study of a single 300 mg enXtra dose. CNS Vital Signs computerized cognitive battery, Visual Analogue Scale, and Epworth Sleepiness Scale measured at baseline, 0.5, 1, 2, and 5 hours post-dose. Published in Advances in Complementary & Alternative Medicine by Eraiah et al. 2023, a Crimson Publishers title that PubMed does not index, and funded by OmniActive. The same group published a companion 4-week study in Current Research in Complementary & Alternative Medicine. Dosing was 30 minutes after lunch.
62 healthy adults. Single-dose crossover trial with washout.
300 mg enXtra improved alertness, simple reaction time, and correct responses while reducing errors. Correct responses on the Symbol Digit Coding test rose significantly versus placebo at 30 minutes and 2 hours, and Alertness Rating Scale scores at 2 and 5 hours. The multiples quoted for these results are ratios of change from baseline rather than of the scores themselves, which makes the gap sound larger than it is. Simple reaction time improvement sustained over 5 hours. Fatigue on a visual analogue scale fell by 6 to 7 hours post-dose and Epworth Sleepiness Scale scores fell at 1, 2 and 5 hours. Because this report sits outside PubMed it cannot be checked in the usual databases, and the 12-week PubMed-indexed trial found its own Epworth change was not statistically significant.